| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 3B512HJD65 |
| InChI Key | QIEKHLDZKRQLLN-FOIQADDNSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C20H27F2N5O4S |
| Molecular Weight | 471.53 |
| AlogP | 2.04 |
| Hydrogen Bond Acceptor | 8.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 117.42 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 32.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
CMGC protein kinase group
CMGC protein kinase CDK family
CMGC protein kinase CDC2 subfamily
|
- | - | - | 0 | - | |
|
Enzyme
Kinase
Protein Kinase
CMGC protein kinase group
|
- | - | - | 0 | - | |
|
Other cytosolic protein
|
- | - | - | 0 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Breast Neoplasms, Male | 2 | D018567 | ClinicalTrials |
| Fallopian Tube Neoplasms | 2 | D005185 | ClinicalTrials |
| Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4446357 |
| FDA SRS | 3B512HJD65 |
| Guide to Pharmacology | 10426 |
| PDB | WG1 |
| SureChEMBL | SCHEMBL19857421 |